Company news: Wolters Kluwer, NEJM; Teva

Share this article:

The New England Journal of Medicine and Wolters Kluwer Health have signed and agreement that makes the Ovid research platform the exclusive medical aggregator of current non-embargoed NEJM content. Subscribers will also be able to tap into PDFs from 1990 onwards. The previous agreement was HTML access to issues beginning in 1993.

Teva Pharmaceuticals said it closed out the quarter with a 28% increase in sales, to $5.4 billion, compared with $4.4 billion for the same period in 2010. The world's biggest maker of generics said generic sales rose 12% during the quarter, to $3 billion, compared with $2.7 billion in 2010. US generic sales fell 5% but was somewhat offset by a 3% gain in Europe. Branded drug sales rose 68%, to $2.3 billion, compared to $1.3 billion in the fourth quarter of 2010. The company said profit rose 23% during the quarter, reported Bloomberg. Teva bolstered its portfolio in 2011 when it bought Cephalon for $6.8 billion. The purchase added 20 products to the company's footprint as well as entered an OTC agreement with giant Proctor and Gamble.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.